Medicare GLP-1 Bridge: Temporary Access at $50/Month Starts July 2026

The Medicare GLP-1 Bridge is a pragmatic short-term fix, not a permanent coverage solution. Announced by CMS under the Trump administration and set to begin July 1, 2026, the program caps out-of-pocket costs at $50 per month for eligible GLP-1 drugs (like Wegovy, Zepbound, and Saxenda) for Medicare Part D beneficiaries with obesity. Eligibility is based on BMI at the time of therapy initiation, using a three-tier system: BMI ≥ 35 alone qualifies; BMI ≥ 30 qualifies with heart failure, uncontrolled hypertension, or chronic kidney disease; and BMI ≥ 27 qualifies with prediabetes, prior heart attack, stroke, or peripheral artery disease. Existing users simply need their prescriber to attest they met criteria when they started. There is no 12-month prior-use requirement, and beneficiaries are not locked into their current Part D plan—the Bridge operates entirely outside the Part D benefit and payment flow, meaning no plan restriction applies.

The program runs only through December 31, 2027, without a legislative fix to the 2003 MMA ban on covering weight-loss drugs under Part D. Without congressional action or permanent rulemaking, millions of beneficiaries could face a coverage cliff in early 2028, losing access to medications that have shown transformative health benefits. The demonstration does not change drugmaker pricing—the copay cap is set by the program, not by negotiation. The Bridge also does not guarantee continued coverage for patients whose weight changes after initiation. The program is a welcome first step for affordability, but it must be made permanent and expanded to protect against health setbacks and financial shocks. Congress should act now to codify coverage of anti-obesity medications under Medicare Part D and ensure equitable, sustainable access.